Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Absence of PspA or Presence of Antibody to PspA Facilitates the Complement-Dependent Phagocytosis of Pneumococci In Vitro

The Absence of PspA or Presence of Antibody to PspA Facilitates the Complement-Dependent... The Absence of PspA or Presence of Antibody to PspA Facilitates the Complement-Dependent Phagocytosis of Pneumococci In Vitro Bing Ren a , d , Jie Li a , c , Kristopher Genschmer a , Susan K. Hollingshead a and David E. Briles a , b a Departments of Microbiology b Pediatrics, The University of Alabama at Birmingham, Birmingham, Alabama, USA c Department of Molecular Microbiology and Immunology, Oregon Health & Sciences University, Portland, Oregon, USA d Department of Pathology, University of Rochester Medical Center, Rochester, New York, USA ABSTRACT Pneumococcal surface protein A (PspA) is a surface molecule on pneumococci that is required for full virulence in mouse models of infection. PspA has been reported to inhibit complement deposition on the pneumococcal surface. It has been assumed that this decreased complement deposition results in the inefficient phagocytosis of wild-type pneumococci. However, an effect of PspA on phagocytosis had not been shown. Our present studies demonstrated that a loss of PspA by capsular type 3 strains WU2 and A66.1 led to enhanced complement-dependent phagocytosis of the pneumococci by the mouse macrophage cell line J774A.1. This observation was made using human complement as well as mouse complement. Since this enhanced phagocytosis could be blocked by antibody to complement receptor CR3 on J774A.1, it was concluded that PspA's effect on phagocytosis was due to its effect on the amount of deposited complement, which in turn helped opsonize the pneumococci for phagocytosis. Since these studies included new independent mutants lacking PspA, the results provide solid confirmation of the previously reported effects of PspA on pneumococcal virulence and complement deposition. Finally, we showed that antibody to PspA, which is also known to enhance complement deposition, also enhances the phagocytosis of pneumococci in a largely complement-dependent manner. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical and Vaccine Immunology American Society For Microbiology

The Absence of PspA or Presence of Antibody to PspA Facilitates the Complement-Dependent Phagocytosis of Pneumococci In Vitro

The Absence of PspA or Presence of Antibody to PspA Facilitates the Complement-Dependent Phagocytosis of Pneumococci In Vitro

Clinical and Vaccine Immunology , Volume 19 (10): 1574 – Oct 1, 2012

Abstract

The Absence of PspA or Presence of Antibody to PspA Facilitates the Complement-Dependent Phagocytosis of Pneumococci In Vitro Bing Ren a , d , Jie Li a , c , Kristopher Genschmer a , Susan K. Hollingshead a and David E. Briles a , b a Departments of Microbiology b Pediatrics, The University of Alabama at Birmingham, Birmingham, Alabama, USA c Department of Molecular Microbiology and Immunology, Oregon Health & Sciences University, Portland, Oregon, USA d Department of Pathology, University of Rochester Medical Center, Rochester, New York, USA ABSTRACT Pneumococcal surface protein A (PspA) is a surface molecule on pneumococci that is required for full virulence in mouse models of infection. PspA has been reported to inhibit complement deposition on the pneumococcal surface. It has been assumed that this decreased complement deposition results in the inefficient phagocytosis of wild-type pneumococci. However, an effect of PspA on phagocytosis had not been shown. Our present studies demonstrated that a loss of PspA by capsular type 3 strains WU2 and A66.1 led to enhanced complement-dependent phagocytosis of the pneumococci by the mouse macrophage cell line J774A.1. This observation was made using human complement as well as mouse complement. Since this enhanced phagocytosis could be blocked by antibody to complement receptor CR3 on J774A.1, it was concluded that PspA's effect on phagocytosis was due to its effect on the amount of deposited complement, which in turn helped opsonize the pneumococci for phagocytosis. Since these studies included new independent mutants lacking PspA, the results provide solid confirmation of the previously reported effects of PspA on pneumococcal virulence and complement deposition. Finally, we showed that antibody to PspA, which is also known to enhance complement deposition, also enhances the phagocytosis of pneumococci in a largely complement-dependent manner.

Loading next page...
 
/lp/american-society-for-microbiology/the-absence-of-pspa-or-presence-of-antibody-to-pspa-facilitates-the-DqxfduLpGg

References (58)

Publisher
American Society For Microbiology
Copyright
Copyright © 2012 by the American society for Microbiology.
ISSN
1556-6811
eISSN
1556-679X
DOI
10.1128/CVI.00393-12
pmid
22855389
Publisher site
See Article on Publisher Site

Abstract

The Absence of PspA or Presence of Antibody to PspA Facilitates the Complement-Dependent Phagocytosis of Pneumococci In Vitro Bing Ren a , d , Jie Li a , c , Kristopher Genschmer a , Susan K. Hollingshead a and David E. Briles a , b a Departments of Microbiology b Pediatrics, The University of Alabama at Birmingham, Birmingham, Alabama, USA c Department of Molecular Microbiology and Immunology, Oregon Health & Sciences University, Portland, Oregon, USA d Department of Pathology, University of Rochester Medical Center, Rochester, New York, USA ABSTRACT Pneumococcal surface protein A (PspA) is a surface molecule on pneumococci that is required for full virulence in mouse models of infection. PspA has been reported to inhibit complement deposition on the pneumococcal surface. It has been assumed that this decreased complement deposition results in the inefficient phagocytosis of wild-type pneumococci. However, an effect of PspA on phagocytosis had not been shown. Our present studies demonstrated that a loss of PspA by capsular type 3 strains WU2 and A66.1 led to enhanced complement-dependent phagocytosis of the pneumococci by the mouse macrophage cell line J774A.1. This observation was made using human complement as well as mouse complement. Since this enhanced phagocytosis could be blocked by antibody to complement receptor CR3 on J774A.1, it was concluded that PspA's effect on phagocytosis was due to its effect on the amount of deposited complement, which in turn helped opsonize the pneumococci for phagocytosis. Since these studies included new independent mutants lacking PspA, the results provide solid confirmation of the previously reported effects of PspA on pneumococcal virulence and complement deposition. Finally, we showed that antibody to PspA, which is also known to enhance complement deposition, also enhances the phagocytosis of pneumococci in a largely complement-dependent manner.

Journal

Clinical and Vaccine ImmunologyAmerican Society For Microbiology

Published: Oct 1, 2012

There are no references for this article.